AVBP Earnings Date: Nov 16, 2026 (Estimated) — ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AVBP's next earnings date?
ArriVent BioPharma, Inc. (AVBP) is expected to report Q3 2026 earnings on Monday, November 16, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.04 on revenue of $800,000.
How did AVBP do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), ArriVent BioPharma, Inc. posted EPS of -$1.05 versus the -$0.99 estimate, a miss of 7.1%. Revenue was $0. The stock's 1-day post-earnings move was +0.2%.
How much does AVBP stock move after earnings?
AVBP beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.1% (up or down) in the day after earnings.
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.99 | -1.05 | -7.14% | $0 | ❌ Miss | +0.22% | -4.43% | -8.57% |
| 2026-05-11 | Q1 2026 | -0.89 | -0.96 | -7.87% | $0 | ❌ Miss | -0.17% | -6.82% | +5.07% |
| 2026-03-05 | Q4 2025 | -0.86 | -0.78 | +9.30% | $0 | ✅ Beat | -7.21% | -4.57% | -1.11% |
| 2025-11-10 | Q3 2025 | -0.78 | -0.83 | -6.41% | $0 | ❌ Miss | +3.08% | +14.66% | +38.04% |
| 2025-08-11 | Q2 2025 | -0.71 | -0.90 | -26.76% | $0 | ❌ Miss | -3.34% | +8.56% | +10.17% |
| 2025-03-03 | Q4 2024 | -1.10 | -0.61 | +44.55% | $0 | ✅ Beat | -6.69% | -7.37% | -21.69% |
| 2024-11-13 | Q3 2024 | -0.82 | -0.61 | +25.61% | $0 | ✅ Beat | -3.43% | -16.88% | -21.55% |
| 2024-08-14 | Q2 2024 | -0.54 | -0.65 | -20.37% | $0 | ❌ Miss | -0.38% | -0.13% | -0.79% |
Showing last 8 quarters.